Emboli are a common complication of amyloid transthyretin cardiomyopathy (ATTR-CM). This study found that the…
Daysha RobinsonNovember 9, 2022
Clinical awareness and early detection of ATTR-CM may be lacking. One study assessed the degree…
Daysha RobinsonOctober 28, 2022
Data suggests that patients with transthyretin cardiomyopathy (ATTR-CM) have short survival times and high medical…
Daysha RobinsonOctober 28, 2022
Patients with the A97S genotype of ATTR-CM may exhibit functional and structural improvements after tafamidis…
Daysha RobinsonOctober 27, 2022
In patients stabilized on tafamidis, SGLT2 inhibitors may be beneficial for improving outcomes of transthyretin…
Daysha RobinsonOctober 27, 2022
Patients with transthyretin amyloidosis cardiomyopathy (ATTR-CM) are at risk of cardiovascular comorbidities, including atrial fibrillation…
Daysha RobinsonSeptember 15, 2022
The awareness and diagnosis of wild‐type transthyretin amyloid cardiomyopathy (ATTRwt CM) is challenging, despite ATTRwt…
Daysha RobinsonSeptember 15, 2022
Heart failure, among other cardiovascular problems, is a typical manifestation of transthyretin amyloidosis cardiomyopathy (ATTR-CM).…
Daysha RobinsonSeptember 15, 2022
Medication adherence is a critical aspect of treating patients with ATTR-CM and ensuring optimal outcomes.…
Daysha RobinsonSeptember 6, 2022